ReviewJournal of nanobiotechnology2026
The interplay between autophagy and immunogenic cell death: nanomaterial-based strategies for cancer immunotherapy.
Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer immunotherapy has significantly advanced the field of oncology. However, effectiveness of immunotherapy remains limited by tumor heterogeneity, immune evasion, and immunosuppressive tumor microenvironments. Immunogenic cell death (ICD) and autophagy are two interconnected biological mechanisms that play crucial roles in modulating tumor-immune interactions. ICD enhances antitumor immunity through the release of damage-associated molecular patterns (DAMPs), while autophagy affects the immunogenicity and viability of tumor cells in a context-dependent manner. Their complex interaction offers a distinctive platform to enhance immune responses and overcome resistance to immunotherapy. This review emphasizes recent advancements in using nanomaterials to regulate autophagy and ICD in cancer therapy. Various nanoplatforms, including metallic, polymeric, lipid-based, and carbon-based nanoparticles, have been engineered to deliver ICD inducers and autophagy modulators in a targeted TME-responsive manner. We discuss the underlying mechanisms, therapeutic synergies, and translational advantages of these dual-functioning systems. Furthermore, we address critical challenges such as biosafety, tumor specificity, and regulatory hurdles, and we explore strategies including PEGylation, biomimetic coating, and biodegradable carriers to improve clinical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.